Some of the hottest stocks on the market are in the biotech sector. Of these, some of the hottest of the hot are in the NAFLD/NASH space. The reason being is the magnitude of disease prevalence and … [Read more...] about Investing In This Biotech Sector Could Triple Your Net Wealth In 3-Years
Cirrhosis
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
Tumors excrete elevated level of galectin-3 Galectin-3 diminishes T-cells’ ability to kill tumor cells Galectin-3 aids in cancer progression GR-MD-02 is safe, effective, and … [Read more...] about GR-MD-02: Keytrua’s Partner, Cancer’s Nemesis
GALT is Primed for Acquisition or Partnership
Overview Galectin Therapeutics (NASDAQ GALT $5.96) is a leader in the development of a treatment for Non-Alcoholic SteatoHepatitis, an unmet medical need worth billions. Their star drug … [Read more...] about GALT is Primed for Acquisition or Partnership
You must be logged in to post a comment.